Publications & Resources
Get insights and guidance from MLMIC and other leading sources on medical professional liability, risk management, and more.
Category: Physicians
New York Public Health Law Provides Immunity for Facilities and Professionals Responding to COVID-19
New York has enacted the Emergency Disaster Treatment Protection Act, a new statute in the Public Health Law that provides healthcare facilities and professionals immunity from civil or criminal liability when delivering care related to COVID-19.
A new Executive Order issued by New York Governor Cuomo continues certain healthcare and malpractice liability directives outlined in previous Executive Orders that address the COVID-19 pandemic.
Evidence-Based Recommendations to Help Care for COVID-19 Patients in the ICU
New recommendations issued by an international research team offer clinical practice guidelines for physicians treating intensive care unit patients with COVID-19.
Mitigating Cybersecurity Threats During the COVID-19 Pandemic
Experts caution hospitals and healthcare organizations about an increased risk of cyberattacks during the COVID-19 emergency.
Legal Risks and Tips for Volunteer Physicians During the COVID-19 Pandemic
MLMIC’s tips and legal risks for policyholders to consider when volunteering during the COVID-19 pandemic.
Experts Say There is No Evidence NSAIDs are Unsafe for COVID-19 Patients
New research refutes speculation that NSAIDs can negatively impact patients with COVID-19.
Facing COVID-19 in New York: A Letter From MLMIC CMO Dr. John Lombardo
MLMIC CMO describes the heroics of his physician colleagues during the COVID-19 pandemic and expresses his pride in and gratitude for the medical profession.
New Flexibility from CMS Will Help Hospitals Manage the COVID-19 Pandemic
New CMS waivers grant hospitals and healthcare systems a number of temporary flexibilities designed to help manage the COVID-19 pandemic.
CMS has issued new guidance for ambulatory surgery centers (ASCs) used to increase hospital capacity during the COVID-19 pandemic.
When Appropriate, FDA Permits Use of Hydroxychloroquine and Chloroquine to Treat COVID-19
The FDA issued emergency use authorization for anti-malarial drugs hydroxychloroquine and chloroquine to treat COVID-19 patients when deemed appropriate by a healthcare provider.